Phase II Study of BAY 56-3722 in Patients With Recurrent, Unresectable, or Metastatic Renal Cell Carcinoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs BAY 563722 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 10 Jul 2013 Biomarkers information updated
- 08 Jul 2013 New trial record